Geon Investment

Geon Investment Inc. is a venture capital firm established in 2009 and located in Seongnam, South Korea. The firm specializes in providing expansion stage and growth capital to companies primarily in the digital and mobile content, biotechnology, and mobile/online game sectors, as well as movie and music content industries. Geon Investment typically invests between KRW 500 million and KRW 2 billion in equity per transaction, targeting businesses that are poised for growth.

SeungHan Kang

Director

20 past transactions

IDID

Series A in 2022
IDID provides an entertainment platform designed to host short-form entertainment content. The company provides a short-form social entertainment platform that can generate content by superimposing different images on different sound sources.

My Chef

Series B in 2021
My Chef sells home meal kits.

Albam

Series B in 2019
Albam : A mobile based HR Solution that is available for both Managers(Admins) and Staffs in App both IOS & Android. The average HR manager spends 45 minutes a day to calculate time attendance & payroll. With Albam, time is reduced by 70% to only 15 minutes. Albam help enterprises in simplifying and automating their time attendance system to payroll solution. Our easy to use and simple Cloud based Human Resource solution helps companies in reducing the high costs that are often associated in the investment of Time Attendance system which includes the purchase of expensive fingerprint machines and training of IT Personnels. With Albam, employees can clock in and clock out directly right away from their smartphone, clock in and clock out has never been this easier with Albam.

Newploy

Series B in 2019
Founded in 2014, Newploy is a South Korean company that develops a platform for automating payroll tasks using robotic process automation technology. Its software enables businesses to manage and centralize various aspects of staffing needs, including leave management, attendance tracking, work scheduling, and payroll calculation.

swIDch

Series A in 2018
swIDch is an information technology company that provides secure authentication through dynamic codes generated by a patented algorithm, enabling offline authentication in network-less environments. Founded in 2015 and based in London, it serves digital identity and payment contexts by allowing the generation of dynamic credentials and supporting dynamic and static virtual PANs across EMV, contactless, and magnetic stripe payments, giving businesses control over credential validity and offline transaction capabilities.

TILON

Venture Round in 2018
TILON is a company that develops virtualization-based cloud computing solutions and related appliances, backed by patented technology, for government agencies, financial institutions, healthcare, education, manufacturing, and defense. Its core activities include cloud smart workspace and digital asset management, with ongoing expansion into smart messaging and electronic document distribution systems by integrating blockchain-based electronic document processing with virtualization capabilities. The product lineup features virtualization platforms such as Dstation, Astation, iSstation, and Estation, designed to serve a broad range of enterprise customers. By combining secure cloud infrastructure with advanced document processing and asset management, TILON aims to help organizations improve operational efficiency, data security, and collaboration across public and private sectors.

Neuraly

Series A in 2018
Neuraly, Inc. is a clinical-stage biotechnology company based in Germantown, Maryland, focused on developing innovative treatments for neurodegenerative diseases, including Parkinson's and Alzheimer's diseases. Founded in 2016, the company emerged from research led by prominent neuroscientists and has secured exclusive licenses for key patents related to its drug candidates. Neuraly is advancing several compounds, notably NLY01, a neuroprotective agent designed to inhibit pathological microglial activation, and NLY02 and NLY03, which are blood-brain barrier-penetrating kinase inhibitors. The company's approach aims to address the underlying mechanisms of neurodegeneration by targeting glial cell activity and preventing neuronal cell death, with the ultimate goal of improving the quality of life for patients affected by these debilitating conditions.

D&D Pharmatech

Series A in 2018
D&D Pharmatech Co., Ltd., established in 2014 and headquartered in Seongnam, South Korea, is a clinical-stage global biotech company specializing in developing innovative medicines. It focuses on various therapeutic areas, including neurodegenerative diseases, molecular imaging and radiotherapy, fibrotic diseases, and metabolic diseases. The company operates through disease-specific subsidiary companies guided by top-tier medical research faculty, aiming to accelerate the translation of cutting-edge research into lifesaving therapeutic products for patients. D&D Pharmatech's product pipeline is supported by its team of experts in bio-new drug research and development, manufacturing quality control, clinical development, and technology transfer. Additionally, it develops positron emission tomography (PET) imaging biomarkers through Precision Molecular Inc., a wholly-owned subsidiary, and conducts single-cell sequencing related to degenerative brain diseases via Valted Seq, Inc. The company employs technologies such as PEGylation to extend drug administration periods.

OliPass

Venture Round in 2017
OliPass is a biotechnology company based in South Korea, focused on advancing life sciences to enhance the quality of life for individuals globally. The company is engaged in developing its proprietary OliPass PNA platform, which aims to modify nucleobases by introducing a cationic lipid moiety. OliPass's product pipeline includes innovations targeting various health conditions, such as SC Injection, Hypercholesterolemia, chemo and radio-sensitizers, and Type II Diabetes. Through its research and development efforts, OliPass is committed to improving health outcomes and changing perceptions within the life sciences sector.

Sugarhill

Series A in 2017
Sugarhill is a Korean company that develops an online commercial real estate platform called Nemo. The platform enables users to register and promote offices, shops, and shared office properties, while providing information to support reliable transactions and contracts. It aims to improve information symmetry by incorporating private data and also offers furniture and office supplies to help clients outfit and manage office spaces.

Sugarhill

Venture Round in 2016
Sugarhill is a Korean company that develops an online commercial real estate platform called Nemo. The platform enables users to register and promote offices, shops, and shared office properties, while providing information to support reliable transactions and contracts. It aims to improve information symmetry by incorporating private data and also offers furniture and office supplies to help clients outfit and manage office spaces.

Gamfs

Series B in 2015
Online/Mobile game developer

Mobirix

Series C in 2015
Mobirix is a mobile game developer and publisher that creates and distributes mobile games globally, with a focus on casual and mid-core RPG titles. The company aims to deliver engaging experiences across diverse ages and cultures and emphasizes building strong partnerships to support growth. Revenue is primarily generated from in-app purchases and advertising, with additional revenue streams. The company prioritizes player experience in its game design and services.

PICNEKO CREATIVE

Series A in 2015
Peek Neko Creative is a social and mobile game development studio.

JP Company

Series B in 2015
Cosmetic venture

TCE Corporation

Venture Round in 2015
TCE Corporation is a textile manufacturer based in Busan, South Korea, established in 1956. The company specializes in producing a wide range of fabrics, including cotton, blended materials, corduroy, velveteen, denim, and various stretch fabrics, catering to the needs of the textile industry. In addition to its production capabilities, TCE Corporation offers woven fabrics and maintains a sales office in Seoul. The company also has international offices in Shanghai, China, and New York, New York, facilitating its global reach in the textile market.

G plus games

Series B in 2014
G Plus Games Co., Ltd. was founded in 2011 to create a new era of next gen online entertainment in the global market. By employs over 20 veteran developers who experienced to develop triple A online gaming products for many years, their goal is to create Final Bullet, next generation online shooter which can be published in over the world with groundbreaking brand-new technologies, features, functions and contents. As they are an independent studio, fully ready to work with any global publishers, on any platforms, and prepare any of culturalization and localization for game design, arts, digital materials, contents and development schedules in support their corporate vision.

Justnine

Series B in 2013
Justnine Co. Ltd. is a mobile app development company based in Seoul, South Korea, founded in 2005. The company specializes in the creation of online and new platform games, focusing on innovative gameplay experiences. One of its notable developments is the mobile game HELLKID: hook & jump, which showcases its commitment to engaging and entertaining users through interactive applications. Justnine aims to leverage technology to deliver high-quality gaming experiences to a diverse audience.

Vooz Soft

Series A in 2012
Vooz Soft provides mobile contents and other mobile solutions for customers in South Korea.

PMD Academy

Series A in 2010
PMD Academy is an education and training provider based in Seoul, South Korea, specializing in pharmacy, medical, and dental education eligibility tests. The academy offers a comprehensive range of offline and online courses tailored to help students prepare for these critical examinations. By focusing on the specific needs of aspiring healthcare professionals, PMD Academy aims to enhance their educational outcomes and improve their chances of success in obtaining necessary qualifications in the competitive medical field.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.